Researchers build 3D-printed heart out of patient’s donor cells
April 16, 2019
By Neozene

Originally by Conor Hale for FierceBiotech Though it’s much smaller than a human heart—at only 2.5 centimeters, it’s about the size of a rabbit’s—the proof-of-concept still contains a fully vascularized structure, complete with its own cells, ventricles and atria. The cells are capable of contracting, but they still need to be taught to work together in order to pump blood effectively, before being tested as a transplant material in animal models, according to research lead Tal Dvir, a professor at Tel Aviv University’s School of Molecular Cell Biology and Biotechnology and

Read More

Novel two-drug combo teaches immune system to attack cancer
April 8, 2019
By Neozene

The idea of training the immune system to hunt down cancer cells and kill them has been borne out in two FDA-approved CAR-T treatments for lymphoma, Novartis’ Kymriah and Gilead’s Yescarta, both of which involve removing T cells from patients and engineering them to be able to recognize cancer. But what if an effective immune attack against lymphoma could be achieved by injecting drugs directly into tumors? Researchers at Mount Sinai School of Medicine in New York have promising early evidence that this approach, called “in situ vaccination,” could be

Read More

AACR: Clovis’ Rubraca follows Lynparza’s big pancreatic cancer win with phase 2 data
April 2, 2019
By Neozene

AstraZeneca and Merck’s Lynparza earlier this year posted an unprecedented phase 3 win in the pancreatic cancer arena. Now, another drug in its class has shown some early success battling the disease, too. Tuesday at the American Association for Cancer Research annual meeting, investigators released phase 2 data showing Clovis Oncology’s PARP inhibitor, Rubraca, could spur a response among BRCA- or PALB2-mutated pancreatic cancer patients who were sensitive to platinum chemotherapy. Researchers tested the drug in patients whose cancer hadn’t worsened after treatment with chemo, and 37% of them benefited from Rubraca

Read More